Skip to main content
Fig. 6 | Diagnostic Pathology

Fig. 6

From: Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy

Fig. 6

Relationship of different HR combination subgroups and BCSS in the HER-2 negative series (Kaplan–Meier method and log-rank test) Legend: The four different HR combinations were significantly different from the BCSS of the HER-2 negative patients (log-rank, P < 0.001). Among HER-2-negative patients, patients with ER-/PR + phenotype had the worst prognosis, but it was not significantly different from that of patients with ER-/PR- phenotype (P = 0.918), and patients with ER + /PR + phenotype had the best prognosis and the lowest risk. The prognosis of patients with ER + /PR- phenotype was located in the middle of the ER + /PR + phenotype (the best outcome) and ER-/PR + phenotype (the worst outcome) between them (P < 0.001). The overall results were similar to the whole group of patients. Abbreviation: ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2

Back to article page

Diagnostic Pathology

ISSN: 1746-1596

Contact us